Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for blood cancer patients: experimental drug CCS1477 enters human trials

NCT ID NCT04068597

Disease control Sponsor: CellCentric Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called CCS1477 (inobrodib) in people with advanced blood cancers like leukemia, lymphoma, and myeloma that have not responded to standard treatments. The drug is given as an oral capsule, either alone or combined with other cancer medicines. The goal is to see if it is safe and whether it can shrink tumors or improve outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CCS1477 (inobrodib) oral capsule, given alone or with other cancer drugs
What this could lead to
If successful, this could provide a new treatment option for people with advanced blood cancers that have stopped responding to standard therapies.
What could go wrong
This is an early-phase trial, so the drug may not work or could cause serious side effects. It is also a small study, so results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2019

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Provision of consent * ECOG performance status 0-2 * Patients with confirmed (per standard disease specific diagnostic criteria), relapsed or refractory haematological malignancies (NHL, MM and AML) * Must have previously received standard therapy * Adequate organ function Exclusion Criteria: * Intervention with any chemotherapy, investigational agents or other anti-cancer drugs within 14 days or 5 half-lives of the first dose * Major surgical procedure or significant traumatic injury within 4 weeks of the first dose of study treatment * Strong inhibitors of CYP3A4 or CYP3A4 substrates with a narrow therapeutic range taken within 2 weeks of the first dose of study treatment * Strong inducers of CYP3A4 within 4 weeks of the first dose of study treatment * Patients should discontinue statins prior to starting study treatment * CYP2C8 substrates with a narrow therapeutic range taken within 2 weeks of the first dose of study treatment * Any unresolved reversible toxicities from prior therapy \>CTCAE grade 1 at the time of starting study treatment (except alopecia and grade 2 neuropathy) * Any evidence of severe or uncontrolled systemic diseases * Any known uncontrolled inter-current illness * QTcF prolongation (\> 470 msec)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myeloid leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm mature T-cell and NK-cell non-Hodgkin lymphoma myelodysplastic syndrome non-Hodgkin lymphoma plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute myeloid leukemia Haematological malignancy Higher-risk myelodysplastic syndrome Multiple myeloma Non-Hodgkin lymphoma Peripheral T-cell lymphoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    34 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CIOCC Hospital Universitario HM Sanchinarro

    COMPLETED

    Madrid, 28050, Spain

  • Cancer and Haematology Centre

    RECRUITING

    Oxford, OX3 7LE, United Kingdom

  • Community Health Network

    RECRUITING

    Indianapolis, Indiana, 46227, United States

  • Emory Winship Cancer Institute

    RECRUITING

    Atlanta, Georgia, 30322, United States

  • Gartnavel General Hospital

    RECRUITING

    Glasgow, G12 0YN, United Kingdom

  • Gustave Roussy

    COMPLETED

    Villejuif, 94805, France

  • Hospital Clínic de Barcelona

    RECRUITING

    Barcelona, 08036, Spain

  • Hospital Germans Trias i Pujol/ ICO Badalona

    RECRUITING

    Badalona, 08916, Spain

  • Hospital Infanta Leonor

    RECRUITING

    Madrid, 28031, Spain

  • Hospital Universitario 12 de Octubre

    RECRUITING

    Madrid, 28041, Spain

  • Hospital Universitario Gregorio Marañón

    RECRUITING

    Madrid, 28009, Spain

  • Hospital Universitario Ramón y Cajal

    RECRUITING

    Madrid, 28034, Spain

  • Hospital Universitario de La Princesa

    RECRUITING

    Madrid, 28006, Spain

  • Hospital Universitario y Politécnico La Fe de la Comunidad Valenciana

    RECRUITING

    Valencia, 46026, Spain

  • ICO L'Hospitalet (Instituto Catalán de Oncología)

    RECRUITING

    Barcelona, 08908, Spain

  • Imperial College

    RECRUITING

    London, United Kingdom

  • Institute Bergonie

    COMPLETED

    Bordeaux, 33076, France

  • Karolinska Comprehensive Cancer Center

    COMPLETED

    Stockholm, Sweden

  • Leicester Royal Infirmary

    RECRUITING

    Leicester, United Kingdom

  • NIHR University College London Clinical Research Facility

    RECRUITING

    London, W1T 7HA, United Kingdom

  • Nebraska Cancer Specialists

    RECRUITING

    Omaha, Nebraska, 68130, United States

  • Newcastle upon Tyne Hospitals

    RECRUITING

    Newcastle upon Tyne, United Kingdom

  • Nottingham University Hospitals NHS Trust

    RECRUITING

    Nottingham, NG5 1PB, United Kingdom

  • Penn Medicine - Abramson Cancer Center Perelman

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • Royal Derby Hospital

    RECRUITING

    Derby, DE22 3NE, United Kingdom

  • Royal Stoke University Hospital

    RECRUITING

    Stoke-on-Trent, ST4 6QG, United Kingdom

  • Sarah Cannon Research Institute UK

    RECRUITING

    London, W1G 6AD, United Kingdom

  • St Bartholomew's Hospital

    RECRUITING

    London, EC1A 7BE, United Kingdom

  • The Center for Cancer and Blood Disorders (CCBD)

    RECRUITING

    Bethesda, Maryland, 20817, United States

  • The Christie Hospital

    RECRUITING

    Manchester, United Kingdom

  • The Clatterbridge Cancer Centre NHS Foundation Trust,

    RECRUITING

    Bebington, CH63 4JY, United Kingdom

  • The Royal Marsden

    RECRUITING

    Sutton, Surrey, SM2 5PT, United Kingdom

  • Universidad de Navarra

    RECRUITING

    Pamplona, 31008, Spain

  • University Hospital Vall D'Hebron

    COMPLETED

    Barcelona, 08035, Spain

  • University Hospital of Southampton

    RECRUITING

    Southampton, SO16 6YD, United Kingdom

  • University Hospital of Wales

    RECRUITING

    Cardiff, United Kingdom

  • University Hospitals Bristol

    RECRUITING

    Bristol, United Kingdom

  • University of Nebraska Medical Center

    RECRUITING

    Omaha, Nebraska, 68198-6846, United States

  • Western General Hospital

    RECRUITING

    Edinburgh, EH4 2XU, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.